Advanced lung adenocarcinoma with spinal cord metastasis successfully treated with second EGFR-TKI treatment: a case report and literature review.Lung adenocarcinoma can be accompanied by epidermal growth factor receptor (EGFR) mutation.  Here, we report a case of lung adenocarcinoma with severe spinal cord metastasis that was successfully treated with a second administration of an EGFR-TKI.  The patient received a second administration of an EGFR-TKI (150 mg/day erlotinib).  These results indicate that EGFR-TKI therapy could be a new strategy for the treatment of advanced lung adenocarcinoma with spinal metastasis.
EGFR-TKI
Advanced lung adenocarcinoma with spinal cord metastasis successfully treated with second EGFR-TKI treatment: a case report and literature review.Lung adenocarcinoma can be accompanied by epidermal growth factor receptor (EGFR) mutation.  Here, we report a case of lung adenocarcinoma with severe spinal cord metastasis that was successfully treated with a second administration of an EGFR-TKI.  The patient received a second administration of an EGFR-TKI (150 mg/day erlotinib).  These results indicate that EGFR-TKI therapy could be a new strategy for the treatment of advanced lung adenocarcinoma with spinal metastasis.
EGFR-TKI
Advanced lung adenocarcinoma with spinal cord metastasis successfully treated with second EGFR-TKI treatment: a case report and literature review.Lung adenocarcinoma can be accompanied by epidermal growth factor receptor (EGFR) mutation.  Here, we report a case of lung adenocarcinoma with severe spinal cord metastasis that was successfully treated with a second administration of an EGFR-TKI.  The patient received a second administration of an EGFR-TKI (150 mg/day erlotinib).  These results indicate that EGFR-TKI therapy could be a new strategy for the treatment of advanced lung adenocarcinoma with spinal metastasis.
EGFR-TKI